menu

Achieving Success in IgAN & FSGS: Expert Insights on Current and Future Therapies

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Achieving Success in IgAN & FSGS: Expert Insights on Current and Future Therapies  

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Can you do better than the experts in treating immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)? Using case-based vignettes, chairperson Siân Griffin, MD, PhD, and faculty members Jürgen Floege, MD, and Loreto Gesualdo, MD, will provide expert analysis regarding the value of lowering proteinuria and offer insights on applying clinical trial data to the unique challenges of managing advanced nephropathy. Learn how novel mechanisms, innovative treatments, and emerging data are achieving successful outcomes in patients with IgAN and FSGS.   

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Can you do better than the experts in treating immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)? Using case-based vignettes, chairperson Siân Griffin, MD, PhD, and faculty members Jürgen Floege, MD, and Loreto Gesualdo, MD, will provide expert analysis regarding the value of lowering proteinuria and offer insights on applying clinical trial data to the unique challenges of managing advanced nephropathy. Learn how novel mechanisms, innovative treatments, and emerging data are achieving successful outcomes in patients with IgAN and FSGS.   

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

Facebook Comments

Schedule2 May 2024